Pantrol (Pantoprazole) is indicated where suppression of acid secretion is of therapeutic benefit, such as - peptic ulcer diseases, GERD,treatment of ulcer resistant to H2 receptor antagonists, treatment of ulcers induced by NSAIDs, gastrointestinal bleeding from stress or acid peptic disease, eradication of Helicobacter pylori, Zollinger-Ellison syndrome, prophylaxis for acid aspiration syndrome during induction of anesthesia.

Prophylaxis of NSAID-associated gastric or duodenal ulcer in patients with an increased risk of gastroduodenal complications who require continued NSAID treatment: 20 mg daily. Gastro-oesophageal reflux disease: 20-40 mg daily in the morning for 4 weeks, continued for further 4 weeks if not fully healed; maintenance 20 mg daily, increased to 40 mg daily if symptoms return. Duodenal ulcer: 40 mg daily in the morning for 2 weeks, continued for further 2 weeks if not fully healed. By mouth, benign gastric ulcer:40 mg daily in the morning for 4 weeks, continued for further 4 weeks if not fully healed. Zollinger-Ellison syndrome (and other hypersecretory conditions):initially 80 mg once daily adjusted according to response (ELDERLY max. 40 mg daily); daily doses above 80 mg should be given in 2 divided doses. Children:There are no adequate and well controlled studies in children